LETTERS TO THE EDITOR

Cellular mechanisms of acute lung injury: implications for future treatment in the adult respiratory distress syndrome

Although I agree that antibodies to adhesive molecules will have a role in treating the adult respiratory distress syndrome (ARDS), as neutrophil activation by C5a forms the basis of the injury I cannot understand why Drs S C Donnelly and C Haslett (April 1992;47: 260-3) fail to give credit to the overriding importance of endotoxaemia. Since there are so many mechanisms and mediators concerned in ARDS, just as there are in Gram negative bacterial shock, there has to be a common trigger—that is, lipopolysaccharide (cf fig 2).

It seems that mistrust has arisen from the results of two sets of experiments conducted by Haslett et al, in particular the one in which a synergistic effect of a small dose of lipopolysaccharide and C5a was seen. Yet in fact endotoxin itself produces C5a. In my experience conducted in 1970-72 it was clear that endotoxin caused acute lung injury with all the features of ARDS. The details of the mechanisms were reviewed by Brigham and Meyrick in 1986.

In recent years several groups have described endotoxaemia at the onset of ARDS. Thus I feel sure that the emphasis will switch to means of combating endotoxaemia.

E N WARDLE
21 Common Road, North Leigh, Oxford OX8 6RD


AUTHORS' REPLY Dr Wardle's letter implies that the pathogenesis of ARDS was sorted out in 1970-2. Unfortunately, this is not the case. There is insufficient evidence at present to regard endotoxin as the central mediator of overriding importance in ARDS. Brigham's group used sheep, which are uniquely sensitive to low concentrations of endotoxin that have little effect as a single agent in other species. Although endotoxin does cause lung oedema due to endothelial damage, this model does not come close to mimicking the complex histological events of full blown ARDS. Although models such as this have proved useful for studies of endothelial injury, most workers would agree that there is, as yet, no ideal model of established ARDS.

The search for a final common mediator in ARDS, as in bronchial asthma, has so far proved disappointing. Endotoxin is undoubtedly an important mediator and, as we discussed in our article, it may exert both direct effects and indirect effects in concert with other mediators, which themselves may assume prominence in the near future. Further, should endotoxaemia be a critical event at some stage of ARDS development, the resultant pathogenic mediator cas-
cades may rapidly move on to stages that do not critically involve endotoxin. Thus with our present awareness of the complexity of factors concerned in the initiation and inflammatory tissue injury we cannot subscribe to a blinkered view of the overriding importance of endotoxin, and it would seem premature and imprudent at present to over emphasise combating endotoxin as a single treatment option at the expense of other options (or combinations thereof) that will soon become available.

CHRIS HASLETT
S C DONNELLY
Respiratory Medicine Unit, Department of Medicine (RIE)
City Hospital, Edinburgh EH10 5SB

Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy with carboplatin, etoposide, and epirubicin

I read with great interest, in the May edition of Thorax (1992;47:369-71), the article by Dr PH Collard and colleagues from Belgium on the treatment of relapse of small cell lung cancer by the combination chemotherapy, in particular carboplatin, etoposide, and epirubicin. The general feeling among workers in this area, particularly in the UK, has been that there is little to be gained from repeated courses of chemotherapy in small cell lung cancer, after an initial set of six to eight courses over a similar period of time.

Quality of life has always been an issue in subjecting patients to repeated courses of combination chemotherapy. For some years, however, I have been using repeated courses of combination chemotherapy in small cell lung cancer and found results similar to those in this article.

In South Lincolnshire I see on average 120 new patients a year with lung cancer, of whom 50-60% have chemotherapy. Although the numbers surviving for long periods with combination chemotherapy are small, none of the less I believe that in selected patients, usually those with limited disease, repeated courses should be considered. In my experience in this group the quality of life has been good, running equally alongside the quantity.

I hope that as a result of the article by Dr Collard and others more patients with small cell carcinoma of lung will be considered for repeated courses.

C R NYMAN
Pilgrim Hospital, Boston, Lincs PE21 9QS

Barcelona's asthma epidemics

The article by Dr C Picado about asthma induced by soya bean dust (March 1992;47: 197-200) makes intriguing reading. Barcelona's asthma epidemic had several unusual features, which I believe suggest that attacks might be due to a novel immunological mechanism. These features include the unusually explosive nature of attacks, which were severe but short in duration; their occurrence in some with mild asthma or in smokers; the absence of a late response; and the difficulty of reproducing attacks with challenge by standard soya bean allergen.

The seeds of leguminous plants (such as soya beans) are a rich source of lectins, which may be present in order to bind specific carbohydrates present on symbiotic nitrogen fixing microorganisms, but are also potent T cell mitogens. Inhalation of another lymphocyte mitogen (lipopolysaccharide) has been suggested as the cause of bronchoconstriction, mucus secretion, fever, and fibrosis in byssinosis. Different lectins have subtly differing mechanisms of action and are potent activators of interleukin-4 producing helper T cells, which are abundant in the bronchial epithelium in patients with asthma. Chronic inflammation of the lungs might cause local recruitment of additional T cells, explaining the apparent additive effect of cigarette smoking.

PETER OPENSHAV
Respiratory and General Medicine, Department of Medicine, St Mary's Hospital Medical School, London W2 1PG

1 Sharon N, Liss H. Lectins as cell recognition molecules. Science 1989;246:227-34.

BOOK NOTE


This book is in a class of its own. It is clear, succinct, full of information, and a pleasure to read—indeed "a useful and practical guide for the ordinary non-specialized doctor or health professional who will meet tuberculosis in the course of his work." The book begins with a general background to the worldwide problem of tuberculosis. A simple scheme of do's and don'ts in tuberculosis, presented in the first few pages of the book, would alone go a long way towards eliminating the incidence of infectious tuberculosis. There are sections on the clinical presentations of tuberculosis, including those related to HIV infection, and the chapter on child tuberculosis is especially good. The chapter on the treatment of tuberculosis gives a welcome emphasis on accurate diagnosis, supervised treatment, management of defaulters, and ensuring that the complete course of chemotherapy is taken, preferably in the context of a national tuberculosis programme. The inclusion of 12 month regimens of treatment, which are no longer recommended, is probably unnecessary. Two features of the book are particularly helpful: bold print emphasises the key points very effectively and the case reports provide excellent and informative illustrations. The advice on the treatment of their electives as helpful gifts to their hosts. The clarity of the book makes it of particular value for those in countries where tuberculosis is common and where English is not their first language. This book cannot be too widely read if we are to eradicate this curable but still widespread disease.—GB
Barcelona's asthma epidemics.

P Openshaw

Thorax 1992 47: 668
doi: 10.1136/thx.47.8.668-c

Updated information and services can be found at:
http://thorax.bmj.com/content/47/8/668.4.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/